Endometrial cancer is the sixth most commonly occurring cancer in women, and early and accurate detection is linked to increased survival. However, currently, around a third of patients are diagnosed at an advanced stage. MiMARK aims to improve the technology available for diagnosis, with a focus on biomarker discovery, verification, and validation. Their solution, WomEC, is an in vitro diagnostic tool that determines 5 protein biomarkers in uterine fluid samples to provide diagnosis to 100% of patients, rule out endometrial cancer with great specificity, and provide information on the histological subtype of the tumor to guide surgical treatment. This is particularly important as current diagnosis using pipelle biopsy fails to diagnose in up to 30% of patients and provides an inaccurate diagnosis in up to 55% of cases, leading to invasive diagnosis using hysteroscopy.